SIM
PCRX icon

Spark Investment Management’s Pacira BioSciences PCRX Stock Holding History

Spark Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-46,300
Closed -$1.5M – 872
2016
Q4 		$1.5M Buy
+46,300
New +$1.55M 0.12% 259
2014
Q4 		– Sell
-11,400
Closed -$1.1M – 780
2014
Q3 		$1.1M Buy
+11,400
New +$1.11M 0.17% 193

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Spark Investment Management's PCRX Position: Q1 2017 in Review

Spark Investment Management sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 46,300 shares — an estimated $1.5M sold.

Spark Investment Management first reported a position in PCRX in Q3 2014 and held it in 2 quarters. The position peaked at $1.5M in Q4 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

  • Spark Investment Management reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
  • Spark Investment Management sold 46,300 Pacira BioSciences shares in Q1 2017, an estimated $1.5M.
  • Spark Investment Management first reported a position in Pacira BioSciences in Q3 2014 and held it in 2 quarters.
  • Spark Investment Management's Pacira BioSciences position peaked at $1.5M in Q4 2016.
  • 192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Spark Investment Management's 13F filing for Q1 2017, filed 11 May 2017.